Literature DB >> 8390056

Tumor necrosis factor activities and cancer therapy--a perspective.

R S Sidhu1, A P Bollon.   

Abstract

Tumor necrosis factor (TNF) is a multifunctional cytokine which has excited and fascinated numerous investigators and commercial entities due to its promise as a therapeutic agent against cancer and as a target for drugs treating septic shock. TNF is a protein having cytotoxic, cytostatic, immunomodulatory as well as several other activities and is also involved in septic shock. This review covers the structure of TNF and its receptors, various in vitro activities and in vivo activities based on studies in animal model systems. The role of TNF as an anticancer therapeutic agent, based on various phase I and phase II clinical studies, has also been considered. The review concludes with several considerations for increasing the therapeutic utility of TNF in terms of targeting, toxicity and half-life.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8390056     DOI: 10.1016/0163-7258(93)90037-e

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  21 in total

Review 1.  The functions of cytokines and their uses in toxicology.

Authors:  J R Foster
Journal:  Int J Exp Pathol       Date:  2001-06       Impact factor: 1.925

2.  Synergistic activation of NF-kappaB by tumor necrosis factor alpha and gamma interferon via enhanced I kappaB alpha degradation and de novo I kappaBbeta degradation.

Authors:  J L Cheshire; A S Baldwin
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

Review 3.  TNF receptor 2 pathway: drug target for autoimmune diseases.

Authors:  Denise Faustman; Miriam Davis
Journal:  Nat Rev Drug Discov       Date:  2010-05-21       Impact factor: 84.694

Review 4.  Biological pathways involved in the development of inflammatory bowel disease.

Authors:  Mateja Zemljic; Bozena Pejkovic; Ivan Krajnc; Saska Lipovsek
Journal:  Wien Klin Wochenschr       Date:  2014-09-26       Impact factor: 1.704

5.  GlycA is a Novel Marker of Inflammation Among Non-Critically Ill Hospitalized Patients with Type 2 Diabetes.

Authors:  Kathleen Dungan; Philip Binkley; Kwame Osei
Journal:  Inflammation       Date:  2015       Impact factor: 4.092

6.  Stable Escherichia coli-Clostridium acetobutylicum shuttle vector for secretion of murine tumor necrosis factor alpha.

Authors:  J Theys; S Nuyts; W Landuyt; L Van Mellaert; C Dillen; M Böhringer; P Dürre; P Lambin; J Anné
Journal:  Appl Environ Microbiol       Date:  1999-10       Impact factor: 4.792

7.  Multifaceted inhibition of anti-tumour immune mechanisms by soluble tumour necrosis factor receptor type I.

Authors:  C L Selinsky; K L Boroughs; W A Halsey; M D Howell
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

8.  Influence of cytokines on mdr1 expression in human colon carcinoma cell lines: increased cytotoxicity of MDR relevant drugs.

Authors:  W Walther; U Stein
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

9.  The inflammatory cytokine tumor necrosis factor modulates the expression of Salmonella typhimurium effector proteins.

Authors:  Jun Ma; Yong-Guo Zhang; Yinglin Xia; Jun Sun
Journal:  J Inflamm (Lond)       Date:  2010-08-12       Impact factor: 4.981

10.  The effect of tumor necrosis factor-alpha and cAMP on induction of AP-1 activity in MA-10 tumor Leydig cells.

Authors:  X Li; K H Hales; G Watanabe; R J Lee; R G Pestell; D B Hales
Journal:  Endocrine       Date:  1997-06       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.